Chronic lymphocytic leukemia (CLL) is a disorder characterized by morphologically mature but immunologically less mature lymphocytes, which accumulate in the bone marrow, lymphatic tissue and blood. CLL generally affects the older population and is incurable, however, several novel treatment approaches have developed to improve outcomes of patients with CLL and there is an increasing use of minimal residual disease (MRD) in disease monitoring. In this podcast, Lydia Scarfò, of Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Othman Al-Sawaf of the University Hospital of Cologne, Cologne, Germany, and Tanya Siddiqi, from City of Hope, Duarte, CA discuss key developments in the treatment of CLL presented at this years EHA meeting.
The post CLL: MRD and first-in class agents appeared first on VJHemOnc.
